Evidence map›Paper›PMID 36294858›Full record

ArticleJournal of personalized medicine2022

Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?

Kenneth Blum, Catherine A Dennen, Igor Elman, Abdalla Bowirrat, Panayotis K Thanos, Rajendra D Badgaiyan, B William Downs, Debasis Bagchi, David Baron, Eric R Braverman and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Validity of mental and physical stress models.Neuroscience and biobehavioral reviews · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Neurogenetics and Epigenetics of Loneliness.Psychology research and behavior management · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 4 countries.

Kenneth BlumThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX 78701, USA.ORCID 0000-0001-6727-803X
Catherine A DennenThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX 78701, USA.
Igor ElmanMedicine, Boston Children's Hospital, Boston, MA 02115, USA.
Abdalla BowirratDepartment of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel 40700, Israel.ORCID 0000-0001-8185-0688
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, Clinical Research Institute on Addictions, University at Buffalo, Buffalo, NY 14203, USA.
Rajendra D BadgaiyanDepartment of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, Long School of Medicine, University of Texas Medical Center, San Antonio, TX 78229, USA.ORCID 0000-0001-5586-5114
B William DownsDivision of Precision Nutrition, Victory Nutrition International, LLC., Lederoch, PA 19438, USA.ORCID 0000-0003-2096-8265
Debasis BagchiDivision of Precision Nutrition, Victory Nutrition International, LLC., Lederoch, PA 19438, USA.
David BaronCenter for Behavioral Health & Sports, Exercise, Psychiatry, Western University Health Sciences, Pomona, CA 91766, USA.
Eric R BravermanThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX 78701, USA.
Ashim GuptaFuture Biologics, Lawrenceville, GA 30043, USA.ORCID 0000-0003-1224-2755
Richard GreenThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX 78701, USA.
Thomas McLaughlinThe Kenneth Blum Behavioral & Neurogenetic Institute, LLC., Austin, TX 78701, USA.
Debmalya BarhCentre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur 721172, India.ORCID 0000-0002-2557-7768
Mark S GoldDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.
NeuroGenetic Pharmaceuticals (United States) · USAriel University · ILCambridge Health Alliance · USClinical Research Institute · USEötvös Loránd University · HUInstitute of Bioinformatics and Applied Biotechnology · INTexas Medical Center · USTexas Southern University · USThomas Jefferson University Hospital · USWashington University in St. Louis · USWestern University of Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reward Deficiency Syndrome (RDS) is defined as a breakdown of reward neurotransmission that results in a wide range of addictive, compulsive, and impulsive behaviors. RDS is caused by a combination of environmental (epigenetic) influences and DNA-based (genetic) neurotransmission deficits that interfere with the normal satisfaction of human physiological drives (i.e., food, water, and sex). An essential feature of RDS is the lack of integration between perception, cognition, and emotions that occurs because of (1) significant dopaminergic surges in motivation, reward, and learning centers causing neuroplasticity in the striato-thalamic-frontal cortical loop; (2) hypo-functionality of the excitatory glutamatergic afferents from the amygdala-hippocampus complex. A large volume of literature regarding the known neurogenetic and psychological underpinnings of RDS has revealed a significant risk of dopaminergic gene polymorphic allele overlap between cohorts of depression and subsets of schizophrenia. The suggestion is that instead of alcohol, opioids, gambling disorders, etc. being endophenotypes, the true phenotype is RDS. Additionally, reward deficiency can result from depleted or hereditary hypodopaminergia, which can manifest as a variety of personality traits and mental/medical disorders that have been linked to genetic studies with dopamine-depleting alleles. The carrying of known DNA antecedents, including epigenetic insults, results in a life-long vulnerability to RDS conditions and addictive behaviors. Epigenetic repair of hypodopaminergia, the causative basis of addictive behaviors, may involve precision DNA-guided therapy achieved by combining the Genetic Addiction Risk Severity (GARS) test with a researched neutraceutical having a number of variant names, including KB220Z. This nutraceutical formulation with pro-dopamine regulatory capabilities has been studied and published in peer-reviewed journals, mostly from our laboratory. Finally, it is our opinion that RDS should be given an ICD code and deserves to be included in the DSM-VI because while the DSM features symptomology, it is equally important to feature etiological roots as portrayed in the RDS model.

Indexed as

addictionbrain reward cascadedopamine homeostasisepigeneticsGenetic Addiction Risk Severity (GARS) testhypodopaminergiapro-dopamine regulation (KB220Z)Reward Deficiency Syndrome (RDS)

Identifiers

PMID36294858
PMCPMC9604605
OpenAlexW4306391370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.